The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
Open accessAbstract
Molecular alterations in malignant disease result in the expression or upregulations of various targets that can be used for imaging and treatment with radiopharmaceuticals. This theranostic principle has acquired greater importance in personalized medicine in recent years, particularly in oncology, where advanced tumors can be treated effectively with low side effects. Since the pioneering use of 131I in differentiated thyroid cancer in the 1940s, remarkable achievements in nuclear medicine endoradiotherapy have been demonstrated, mainly in the treatment of neuroendocrine neoplasms by using 177Lu-labeled somatostatin analogs or in the treatment of advanced prostate cancer using prostate-specific membrane antigen–directed radionuclide therapy. Besides that, this review focuses on promising novel radiopharmaceuticals and describes their preclinical and clinical status. Radiolabeled antibodies, such as 131I-omburtamab directed against the B7-H3 protein on the surface of neuroblastoma cells; HuMab-5B1, a 89Zr/177Lu-labeled antibody for the treatment of CA19-9–expressing malignancies; and 177Lu-lilotomab, a CD37 antibody for the treatment of B-cell lymphomas, are being highlighted. The neurotensin receptor ligand 111In/177Lu-3B-227 has demonstrated high potential in imaging and therapy for several malignancies (e.g., pancreatic adenocarcinomas). Targeting of the fibroblast activation protein is currently being explored for different tumor entities using PET imaging with the fibroblast activation protein inhibitor (FAPI) 68Ga-FAPI-04, and the first therapeutic applications of 90Y-FAPI-04 have been applied. After 2 decades of rapid development in theranostics, a variety of new targets are available for further clinical investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PubChem Substance and Compound databases
Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv951 · Cited by 5,436 · cited 1×
“CA19-9 is a tetrasaccharide (54) and part of glycoproteins and glycolipids on the surface of tumor cells (53).”
BackgroundAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“These 2 theranostic approaches, as well as the therapy of osseous metastases of prostate cancer with 223Ra (4,9,10), have unequivocally demonstrated that radionuclide therapy can be applied not only to thyroid cancer but also to other solid tumors.”
BackgroundPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Theranostics: Combining Imaging and Therapy
Kelkar, S. S., & Reineke, T. M. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200151q · Cited by 1,385
Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,100
Pavel, M., O''Toole, D., Costa, F., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E., Knigge, U., Salazar, R., Pape, U.-F., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,041
Lindner, T., Loktev, A., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 935
A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
Loktev, A., Lindner, T., Mier, W., Debus, J., Altmann, A., Jäger, D., Giesel, F., Kratochwil, C., Barthe, P., Roumestand, C., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210435 · Cited by 777
Giesel, F. L., Kratochwil, C., Lindner, T., Marschalek, M. M., Loktev, A., Lehnert, W., Debus, J., Jäger, D., Flechsig, P., Altmann, A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215913 · Cited by 740
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O., & Gorrell, M. D. (2014) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300095 · Cited by 496
RADIOACTIVE IODINE THERAPY: Effect on Functioning Metastases of Adenocarcinoma of the Thyroid
SEIDLIN, S. M. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870490016004 · Cited by 427
Kratochwil, C., Bruchertseifer, F., Rathke, H., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 421
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 354
CA 19-9: Biochemical and Clinical Aspects
Scarà, S., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_15 · Cited by 351
Lee, S. L. (2012) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328357fa0c · Cited by 307
Souweidane, M. M., Kramer, K., Pandit-Taskar, N., Zhou, Z., Haque, S., Zanzonico, P., Carrasquillo, J. A., Lyashchenko, S. K., Thakur, S. B., Donzelli, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30322-x · Cited by 267
Welt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., & Old, L. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1193 · Cited by 266
Wild, D., Fani, M., Fischer, R., Del Pozzo, L., Kaul, F., Krebs, S., Fischer, R., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 266
Self-citationHERTZ, S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870190005002 · Cited by 263
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
Kramer, K., Kushner, B. H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., Zanzonico, P., Humm, J. L., Xu, H., Wolden, S. L., Souweidane, M. M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0038-7 · Cited by 247
Maurer, T., Robu, S., Schottelius, M., Schwamborn, K., Rauscher, I., van den Berg, N. S., van Leeuwen, F. W. B., Haller, B., Horn, T., Heck, M. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.013 · Cited by 243
Self-citationProstate-Specific Membrane Antigen Ligands for Imaging and Therapy
Eiber, M., Fendler, W. P., Rowe, S. P., Calais, J., Hofman, M. S., Maurer, T., Schwarzenboeck, S. M., Kratowchil, C., Herrmann, K., & Giesel, F. L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186767 · Cited by 241
Self-citationRobu, S., Schottelius, M., Eiber, M. J., Maurer, T., Gschwend, J. E., Schwaiger, M., & Wester, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178939 · Cited by 235
Self-citationProstate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer
Maurer, T., Weirich, G., Schottelius, M., Weineisen, M., Frisch, B., Okur, A., Kübler, H., Thalgott, M., Navab, N., Schwaiger, M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.034 · Cited by 233
Self-citationThe third group of the B7‐CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3
Janakiram, M., Shah, U. A., Liu, W., Zhao, A., Schoenberg, M. P., & Zang, X. (2017) · Immunological Reviews · doi:10.1111/imr.12521 · Cited by 225
The role of neurotensin in central nervous system pathophysiology: What is the evidence?
St-Gelais, F., Jomphe, C., & Trudeau, L.-É. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0627 · Cited by 207
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Wild, D., Fani, M., Behe, M., Brink, I., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., & Weber, W. A. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088922 · Cited by 183
Self-citationNicolas, G. P., Schreiter, N., Kaul, F., Uiters, J., Bouterfa, H., Kaufmann, J., Erlanger, T. E., Cathomas, R., Christ, E., Fani, M., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199760 · Cited by 171
Modak, S. I., Kramer, K., Gultekin, S. H., Guo, H.-F., & Cheung, N. V. (2001) · PubMed · Cited by 164
Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity
Sawada, R., Sun, S.-M., Wu, X., Hong, F., Ragupathi, G., Livingston, P. O., & Scholz, W. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2640 · Cited by 105
Baum, R. P., Singh, A., Schuchardt, C., Kulkarni, H., Klette, I., Wiessalla, S., Osterkamp, F., Reineke, U., & Smerling, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193847 · Cited by 105
The application of the fibroblast activation protein α-targeted immunotherapy strategy
Jiang, G., Xu, W., Du, J., Zhang, K.-S., Zhang, Q.-G., Wang, X.-W., Liu, Z.-G., Liu, S., Xie, W., Liu, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8098 · Cited by 84
The Future of Nuclear Medicine as an Independent Specialty
Czernin, J. G., Sonni, I., Razmaria, A. A., & Calais, J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220558 · Cited by 78
Emerging role of neurotensin in regulation of the cardiovascular system
Osadchii, O. E. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.025 · Cited by 68
Viola, N. T., Rice, S. L., Carlin, S., Wu, X., Evans, M. J., Sevak, K. K., Drobjnak, M., Ragupathi, G., Sawada, R., Scholz, W. W., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.119867 · Cited by 67
Schulz, J., Rohracker, M., Stiebler, M., Goldschmidt, J., Stöber, F., Noriega, M., Pethe, A., Lukas, M., Osterkamp, F., Reineke, U., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185140 · Cited by 60
A Review of the Role of Neurotensin and Its Receptors in Colorectal Cancer
Qiu, S., Pellino, G., Fiorentino, F., Rasheed, S., Darzi, A. W., Tekkis, P. P., & Kontovounisios, C. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/6456257 · Cited by 58
Radioimmunotherapy for Treatment of Acute Leukemia
Bodet‐Milin, C., Kraeber‐Bodéré, F., Eugène, T., Guérard, F., Gaschet, J., Bailly, C., Mougin‐Degraef, M., Bourgeois, M., Faivre-Chauvet, A., Chérel, M., et al. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.10.007 · Cited by 40
Andersen, J. L., Schrøder, T. J., Christensen, S., Strandbygaard, D., Pallesen, L. T., García-Alai, M., Lindberg, S., Langgård, M., Eskildsen, J., David, L., et al. (2014) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004713030149 · Cited by 38
Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists
Bodei, L., & Weber, W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.205161 · Cited by 30
Self-citationReidy‐Lagunes, D. L., Pandit-Taskar, N. D., Krebs, S. S., Donoghue, J. A. O., Raj, N. P., Cruz, E., Pham, H. M., Lashley, A., Bodei, L., & Weber, W. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4094 · Cited by 10
Self-citationHofman, M. S., Emmett, L., Violet, J. A., Lawrence, N. J., Williams, S., Stockler, M. R., Francis, R. J., Iravani, A., Zhang, A. Y., Martin, A. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.tps332 · Cited by 6
Cited by
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Radiotheranostics: a roadmap for future development
Herrmann, K., Schwaiger, M., Lewis, J. S., Solomon, S. B., McNeil, B. J., Baumann, M., Gambhir, S. S., Hricak, H., & Weissleder, R. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30821-6 · Cited by 327
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Radiolabelling of nanomaterials for medical imaging and therapy
Pellico, J., Gawne, P. J., & T. M. de Rosales, R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00384k · Cited by 304
Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review
Indoria, S., Singh, V., & Hsieh, M.-F. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119314 · Cited by 168
Metadata
- Authors
- Langbein, T., Weber, W. A., & Eiber, M.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2019-09
- Volume
- 60
- Issue
- Supplement 2
- Pages
- 13S-19S
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2972034295
- Cited by
- 269
- References
- 44
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.